Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 22;16(10):e72085.
doi: 10.7759/cureus.72085. eCollection 2024 Oct.

Comparative Effectiveness of Endoscopic Versus Pharmacological Interventions for Variceal Rebleeding in Cirrhosis: A Systematic Review

Affiliations
Review

Comparative Effectiveness of Endoscopic Versus Pharmacological Interventions for Variceal Rebleeding in Cirrhosis: A Systematic Review

Muath M Dabas et al. Cureus. .

Retraction in

Abstract

Variceal bleeding is a critical complication in cirrhotic patients, significantly increasing morbidity and mortality risks, particularly after an initial bleeding episode. This systematic review evaluates and compares the effectiveness of endoscopic and pharmacological interventions in preventing variceal rebleeding. A comprehensive search of major databases, including PubMed, MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science, was conducted to identify studies published within the past decade. The review focused on randomized controlled trials, clinical trials, and meta-analyses that assessed the efficacy and safety of these treatments in adult cirrhotic patients with a history of variceal bleeding. The findings suggest that endoscopic interventions, such as band ligation and early transjugular intrahepatic portosystemic shunt (TIPS) placement, effectively reduce immediate rebleeding rates and improve short-term survival, particularly in high-risk patients with advanced cirrhosis. In contrast, pharmacological strategies, including beta-blockers and vasoactive agents, provide effective long-term management with fewer adverse events, especially in patients with milder liver disease. The review underscores the importance of a personalized treatment approach that integrates both endoscopic and pharmacological therapies to optimize outcomes and reduce the burden of rebleeding. It also highlights the need for further high-quality research to clarify the long-term benefits, impact on quality of life, and cost-effectiveness of these interventions. These insights form the basis for refining clinical guidelines and improving patient-centered care in the management of variceal rebleeding.

Keywords: cirrhosis; endoscopic therapy; pharmacological treatment; rebleeding prevention; variceal bleeding.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. The PRISMA flowchart represents the study selection process.
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

References

    1. Cirrhotic portal hypertension: from pathophysiology to novel therapeutics. Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. World J Gastroenterol. 2020;26:6111–6140. - PMC - PubMed
    1. Management of varices and variceal hemorrhage in liver cirrhosis: a recent update. Diaz-Soto MP, Garcia-Tsao G. Therap Adv Gastroenterol. 2022;15 - PMC - PubMed
    1. Current management strategies for acute esophageal variceal hemorrhage. Fortune B, Garcia-Tsao G. Curr Hepatol Rep. 2014;13:35–42. - PMC - PubMed
    1. The use of nonselective beta blockers for treatment of portal hypertension. Garcia-Tsao G. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718179/ Gastroenterol Hepatol (N Y) 2017;13:617–619. - PMC - PubMed
    1. Endoscopic treatment of esophageal varices in patients with liver cirrhosis. Triantos C, Kalafateli M. World J Gastroenterol. 2014;20:13015–13026. - PMC - PubMed

LinkOut - more resources